Department of Neurology, The Catholic University of Korea, Bucheon St. Mary's Hospital, Bucheon, Korea.
The PDE5 inhibitors have recently been found to have cognitive-enhancing effects in animal models. To investigate the efficacy of repeated dosing with a PDE5 inhibitor on cognitive function and somatization in patients with erectile dysfunction, 27 patients with erectile dysfunction received udenafil (100 mg) at 3-day intervals for 2 months. The international index of erectile function-5 (IIEF-5), a cognitive battery (the Korean version of mini-mental state examination (K-MMSE), the frontal assessment battery (K-FAB), the Seoul verbal learning test) and a physical health questionnaire-15 (PHQ-15) were performed at baseline and at 2 months, following the administration of udenafil. The patients were divided on the basis of their IIEF-5 score into responders (change>7) and non-responders. The mean IIEF-5 score was significantly increased after treatment (7.92±3.83 to 16.33±4.75, P< 0.001). The scores of K-MMSE (27.03±1.58 to 28.07±1.57, P=0.001), K-FAB (13.65±1.96 to 15.41±1.85, P< 0.001) and PHQ-15 (18.92±4.96 to 17.63±4.75, P=0.003) were significantly improved after treatment. In addition, the responders (n=16) had more improved cognitive function (r=0.603, P=0.001) and somatization (r=-0.402, P=0.038) than non-responders (n=11). Repeated dosing with a PDE5 inhibitor seems to improve cognitive function and somatization, as well as erectile function in patients with erectile dysfunction.
Written by:
Shim YS, Pae CU, Kim SW, Kim HW, Kim JC, Koh JS. Are you the author?
Reference: Int J Impot Res. 2011 May 5. Epub ahead of print.
doi: 10.1038/ijir.2011.13
PubMed Abstract
PMID: 21544084
UroToday.com Erectile Dysfunction (ED) Section
